Manganese in Women With Encephalopathy

NCT ID: NCT00985010

Last Updated: 2016-11-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-01-31

Study Completion Date

2005-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective:

Report manganese serum levels and mortality in encephalopathic patients.

Patients and participants:

Consecutive patients aged \> 18 years, with hepatic encephalopathy and informed consent signed by their families.

Interventions:

Patients' clinical characteristics as well as biochemical tests of renal function, hemoglobin, glucose and albumin levels were obtained as well as a blood sample to analyze manganese levels with a graphite furnace atomic absorption spectrometer.

Hypothesis:

There is a difference in the manganese levels between male and female patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Encephalopathy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

hepatic encephalopathy hepatitis C manganese mortality prognosis.

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Consecutive patients aged \> 18 years
* With hepatic encephalopathy
* Informed consent signed by their families

Exclusion Criteria

* Portal bypass surgery
* Cancer of any localization
* Known malignancy and other severe diseases which shorten life expectancy \< 6 months
* Psychiatric illness
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital General "Dr. Darío Fernández Fierro"

UNKNOWN

Sponsor Role collaborator

National Institute of Neurology and Neurosurgery

UNKNOWN

Sponsor Role collaborator

Materno-Perinatal Hospital of the State of Mexico

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Materno-Perinatal Hospital of the State of Mexico

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hugo Mendieta Zerón, PhD

Role: PRINCIPAL_INVESTIGATOR

Materno-Perinatal Hospital of the State of Mexico

Camilo Rios Castañeda, PhD

Role: STUDY_DIRECTOR

National Institute of Neurology and Neurosurgery

Mónica Rodríguez Rodríguez, MD

Role: STUDY_CHAIR

General Hospital "Dr. Darío Fernández Fierro"

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

General Hospital "Dr. Darío Fernández Fierro"

México, D.f., Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mexico

References

Explore related publications, articles, or registry entries linked to this study.

Zeron HM, Rodriguez MR, Montes S, Castaneda CR. Blood manganese levels in patients with hepatic encephalopathy. J Trace Elem Med Biol. 2011 Dec;25(4):225-9. doi: 10.1016/j.jtemb.2011.07.003. Epub 2011 Oct 4.

Reference Type DERIVED
PMID: 21975221 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HGDrDFF-Mn2008

Identifier Type: -

Identifier Source: org_study_id